Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRA | P11474 | 1/20 | 0.50 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.47 |
| ▸ | KMO | O15229 | 2/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | RORC | P51449 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.41 |
| ▸ | PNLIP | P16233 | 1/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.41 |
| ▸ | S100A9 | P06702 | 1/20 | 0.40 |
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30837251 | 0.88 | KMO (0.51) | ESRRAKMO | |
| SCHEMBL20702550 | 0.87 | NOTUM (0.42) | ESRRAMRGPRX4ADRB2EPHX2RORC | |
| SCHEMBL16950345 | 0.86 | KMO (0.42) | ESRRAKMOROCK2SCN9AS100A9 | |
| SCHEMBL24959789 | 0.85 | KMO (0.47) | MRGPRX4KMOROCK2EPHX2SCN9A | |
| SCHEMBL403102 | 0.85 | KMO (0.53) | MRGPRX4KMO | |
| SCHEMBL9526138 | 0.85 | KMO (0.47) | MRGPRX4KMOROCK2EPHX2SCN9A | |
| SCHEMBL1109099 | 0.83 | SLC6A2 (0.48) | MRGPRX4KMOROCK2SCN9AS100A9 | |
| SCHEMBL28012476 | 0.83 | ROCK2 (0.43) | MRGPRX4KMOROCK2EPHX2SLC1A5 | |
| SCHEMBL24436714 | 0.81 | EPHX2 (0.44) | ESRRAEPHX2CREBBP | |
| SCHEMBL16210218 | 0.81 | EPHX2 (0.59) | EPHX2CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | BIOMARIN PHARMACEUTICAL INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-20210171474-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2021-06-10 | — | — | US | disclosed |
| WO-2020257487-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| US-10562897-B2 | Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-02-18 | — | — | US | disclosed |
| US-10246454-B2 | Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2019-04-02 | — | — | US | disclosed |
| US-20180319797-A1 | NOVEL SUBSTITUTED PYRIDO-PIPERAZINONE DERIVATIVES AS GAMMA SECRETASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-11-08 | — | — | US | disclosed |
| EP-2841435-B1 | PYRROLOPYRIDINONE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC (JP) | 2017-09-06 | — | — | EP | disclosed |
| EP-2945944-B1 | NOVEL SUBSTITUTED PYRIDO-PIPERAZINONE DERIVATIVES AS GAMMA SECRETASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-11-09 | — | — | EP | disclosed |
| US-20150353544-A1 | NOVEL SUBSTITUTED PYRIDO-PIPERAZINONE DERIVATIVES AS GAMMA SECRETASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-12-10 | — | — | US | disclosed |
| EP-2945944-A1 | NOVEL SUBSTITUTED PYRIDO-PIPERAZINONE DERIVATIVES AS GAMMA SECRETASE MODULATORS | Janssen Pharmaceutica, N.V. (BE) | 2015-11-25 | — | — | EP | disclosed |
| EP-2841435-A1 | PYRROLOPYRIDINONE DERIVATIVES AS TTX-S BLOCKERS | RaQualia Pharma Inc (JP) | 2015-03-04 | — | — | EP | disclosed |
| WO-2014111457-A1 | NOVEL SUBSTITUTED PYRIDO-PIPERAZINONE DERIVATIVES AS GAMMA SECRETASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-07-24 | — | — | WO | disclosed |
| WO-2013161312-A1 | PYRROLOPYRIDINONE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2013-10-31 | — | — | WO | disclosed |
| US-7358359-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2008-04-15 | — | — | US | disclosed |
| EP-0365913-B1 | Substituted 2-aminothiazoles | BAYER AG (DE) | 1993-11-18 | — | — | EP | disclosed |
| US-5142092-A | Chemical intermediate for making fungicides | BAYER AKTIENGESELLSCHAFT (DE) | 1992-08-25 | — | — | US | disclosed |
| EP-0365914-B1 | FLUORINE-CONTAINING ACETOPHENONES OPTIONALLY HALOGENATED IN THE CH3-GROUP, AND THEIR PREPARATION FROM FLUORINATED BENZONITRILES | BAYER AG (DE) | 1992-07-22 | — | — | EP | disclosed |
| US-5104879-A | ANTIMYCOTICALLY ACTIVE SUBSTITUTED 2-AMINOTHIAZOLES | BAYER AKTIENGESELLSCHAFT (DE) | 1992-04-14 | — | — | US | disclosed |
| EP-0365914-A2 | Fluorine-containing acetophenones optionally halogenated in the CH3-group, and their preparation from fluorinated benzonitriles | BAYER AG (DE) | 1990-05-02 | — | — | EP | disclosed |
| EP-0365913-A2 | Substituted 2-aminothiazoles | BAYER AG (DE) | 1990-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10246454-B2 | Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators | BACE1, BACE2, PSEN1 | ESRRA 1545/4885MRGPRX4 1664/4885KMO 2532/4885 |
| US-20150353544-A1 | NOVEL SUBSTITUTED PYRIDO-PIPERAZINONE DERIVATIVES AS GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | ESRRA 1487/4885MRGPRX4 1103/4885KMO 3045/4885 |
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | XDH, PNPO, AGXT | ESRRA 3622/4885MRGPRX4 1196/4885KMO 248/4885 |
| US-20210171474-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | ESRRA 3622/4885MRGPRX4 1196/4885KMO 248/4885 |
| US-10562897-B2 | Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators | BACE1, BACE2, PSEN1 | ESRRA 1545/4885MRGPRX4 1664/4885KMO 2532/4885 |
| US-20180319797-A1 | NOVEL SUBSTITUTED PYRIDO-PIPERAZINONE DERIVATIVES AS GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | ESRRA 1487/4885MRGPRX4 1103/4885KMO 3045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.